Eight major RCTs of GLP-1RAs have investigated the cardiovascular outcomes, including the ELIXA trial of lixisenatide (250), the EXSCEL trial of exenatide ER (251), the LEARDER trial of liraglutide (252), the SUSTAIN-6 trial of subcutaneous semaglutide (253), the HARMONY trial of albiglutide (228), the REWIND trial of dulaglutide (254), the PIONEER trial of oral semaglutide (255), and the SELECT trial of subcutaneous semaglutide (199)
Prevalence of gallstones in ulcerative colitis and Crohns disease: a systematic review and meta-analysis
GHK-Cus systemic approach means injectable formulations provide benefits beyond the scalp
sinensis and O
Nonalcoholic Fatty Liver Disease: A Feature of the Metabolic Syndrome
Customers can review available products and confirm current stock, vial size, pricing, payment information, and local delivery arrangements directly with our team before placing an order